The purpose of this study is to assess the impact of the BMS-986419 new immediate release (IR) tablet formulation compared to the current enteric (DR) capsule formulation, and to assess the effect of food on the drug levels of the IR tablet formulation in healthy adult participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Specified dose on specified days
Specified dose on specified days
Anaheim Clinical Trials
Anaheim, California, United States
Maximum observed plasma concentration (Cmax)
Time frame: Up to 15 days
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])
Time frame: Up to 15 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Time frame: Up to 15 days
Number of participants with adverse events (AEs)
Time frame: Up to 29 days
Number of participants with vital sign abnormalities
Time frame: Up to 29 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 29 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 29 days
Number of participants with physical examination abnormalities
Time frame: Up to 29 days
Time to attain maximum observed plasma concentration (Tmax)
Time frame: Up to 15 days
Terminal half-life (T-Half)
Time frame: Up to 15 days
Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24))
Time frame: Up to 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.